Background. Outbreaks of acute hepatitis B among inmates of 6 prisons in 3 regions of northern England occurring from 1992 through 1994 were found to be associated with a single hepatitis B virus (HBV) variant, which was carried by 20 of the 24 case patients. We instigated a study of cases of acute hepatitis B to trace the spread and prevalence of this variant.
Britain has adopted a policy of selective, rather than universal, vaccination against hepatitis B virus (HBV) [1] , and outbreaks of acute hepatitis B continue to occur. Vaccination coverage of at-risk groups, which include people with multiple sexual partners, prison inmates, and injection drug users (IDUs), is poor [2] [3] [4] . The molecular epidemiology of the HBV strains associated with these outbreaks has been studied, but results have been confined to reports of outbreaks in institutions [5] [6] [7] [8] [9] [10] and local communities [11, 12] . Investigations have failed to link outbreaks occurring after, we refer to this variant as "HBV PV ," to indicate "prison variant." We extended the investigation to determine the extent to which HBV PV had been circulating in the country. Serum samples that were obtained from case patients with acute hepatitis B during the period 1990-1996 were collected from the following laboratories: the CPHL (119 samples), which receives samples from case patients across a large part of England and Wales-in particular, London, the Home Counties, southeast England, and Trent; the Hull Public Health Laboratory (108 samples), which receives specimen referrals originating in North Humberside; and the Birmingham Public Health Laboratory (70 samples), which receives specimen referrals from the West Midlands. The period 1990-1996 was chosen because it encompassed the period during which the outbreaks occurred in the prisons.
Samples are usually referred from general practitioners and other clinics and institutions to confirm a diagnosis of acute HBV infection. We selected samples solely on the basis of a positive result for IgM antibody to hepatitis B core antigen, which is the marker of acute disease. During the study, we did not investigate any consecutive samples from patients.
Study samples originating from the CPHL were randomly selected (30 samples per year) from the laboratory's serum repository, and those from the Hull and Birmingham laboratories were derived from all the cases of acute hepatitis B diagnosed in the 2 laboratories. Samples obtained by the CPHL in 1991 and 1992 and those obtained by the Birmingham laboratory in 1996 were not available for study. Risk information relating to case patients whose serum samples were referred to the Hull and Birmingham laboratories was evaluated. The paucity of risk information provided with the serum samples referred to the CPHL precluded a similar analysis for the CPHL cases.
PCR amplification of DNA from the HBV S and C genes. Nucleic acid extraction from 100 mL of serum was done by using a guanidinium thiocyanate-silica method [13] . Extracts were subjected to first-round PCR amplification in 50-mL volumes containing 0.7 U of Expand High Fidelity polymerase mix (Roche Diagnostics), 50 mM of each deoxynucleoside triphosphate, 20 pmol of each PCR primer, and 10 mL DNA extract. Primers S5 and S6 were used for first-round amplification of a segment from the HBV S gene [5] , and primers 1763 and 2032R were used for amplification of a segment from the C gene [14] . PCR was performed under the following conditions: denaturing at 94ЊC for 2 min, followed by 30 cycles of 94ЊC for 30 s, 55ЊC for 30 s, and 72ЊC for 60 s, with a final extension at 72ЊC for 2 min. Nested PCR was done under the same conditions, except that 2 mL of the first-round PCR product, as template, and 20 pmol of each inner primer were used. For DNA amplification of the S gene, primers 109 and 585R were used, and primers 1778-E and 2017-B were used for DNA amplification of the C gene [14] . In all PCR experiments, the possibility of cross-contamination was ruled out by the use of appropriate measures, such as negative control samples, aerosol-resistant tips, and separate pre-and post-PCR rooms.
DNA sequencing. PCR products from the outbreak samples from the prisons and from the samples associated with transmission incidents, as detailed in table 1, were purified and submitted for DNA sequencing using the ABI Prism or the ABI BigDye DNA sequencing kits and the ABI 373 or 377 automated sequencer (PE Applied Biosystems). The MegAlign program of the Lasergene package (DNAStar) was used to create multiple alignments and dendrograms, for comparison of the sequences.
Screening for sequence variation in HBV S and C gene amplicons, by denaturing gradient gel electrophoresis (DGGE). DGGE [15] was adapted to screen for sequence variation in DNA amplified from the HBV S and C genes. To generate amplicons suitable for DGGE, one of the inner primers in the nested PCR was replaced with GC-rich "clamping" primers, to prevent the products from undergoing complete denaturation during electrophoresis. To amplify S gene DNA for DGGE, primers 109-clamp (5 -CGCCCGCCGCGCCCCGCGCCCGT-CCCGCCGCCCCCGCCCGATACCACAGACTAGACTCGTG-GTGGAC) and 585R were used. To amplify C gene DNA, primers 1778-E-clamp (5 -CGCCCGCCGCGCCCCGCGCCCGTC-CCGCCGCCCCCGCCCGGACGAATTCCATTGACCCGTAT-AAAGAATT) and 2017R-B were used. The final PCR products for the S and C genes were 517 bp and 298 bp, respectively.
Optimization experiments were done by using the first 17 samples received from the Hull laboratory for which the sequences of the HBV S and C genes were determined. In 3 samples, the sequences of both fragments were identical to those of HBV PV . In the other 14 samples, a 1-28-bp difference in the S gene and a 1-24-bp difference in the C gene were found. Varying the DGGE conditions showed that, for DGGE to achieve a 1-bp discrimination between PCR products, the gel needs to possess a gradient of 10%-60% of denaturants. A 10%-denaturant mix comprises 8% acrylamide (w/v; Protogel, National Diagnostics), 0.6ϫ Tris-acetate EDTA buffer, 4% formamide (v/v), and 0.7 mol/L urea, whereas a 60%-denaturant mix comprises 8% acrylamide, 0.6ϫ Tris-acetate-disodium EDTA buffer, 24% formamide, and 4.2 mol/L urea. Gradient gels were poured by using Ingeny Phor U2 electrophoresis apparatus (Genetic Research Instrumentation Ltd.), in accordance with the manufacturer's instructions. PCR products (2-7 mL) obtained with the "clamping" primers were mixed with an equal volume of loading buffer and were loaded into wells (each gel can accommodate up to 48 samples). Separate gels were used to screen for variations in the sequences of the HBV S and C gene amplicons. Wells at the ends and the middle of the gels were loaded with PCR products from plasmids that had been constructed to carry HBV PV S or C gene inserts. Electrophoresis was done in 0.6ϫ Tris-acetate-disodium EDTA buffer at 60ЊC and at 100 V, for 18 h. DNA bands were visualized by UV transillumination after staining with SYBR Green I (Flowgen). Serum samples were considered to carry HBV PV if the PCR products derived from both the HBV S and C genes migrated to the same gel position as that for the referent HBV PV bands. Search for HBV PV involvement in HBV-associated outbreaks and other transmission incidents. The CPHL had been conducting molecular investigations into hepatitis B outbreaks since 1993 [5] . Records of the investigations that involved molecular epidemiology were reviewed to determine the extent to which HBV PV could be identified in the outbreaks. Figure  2 illustrates the outcome of a DGGE study of PCR products from the HBV C gene that were derived from the entire set of serum samples referred to the Hull laboratory from 1990 through 1996. The trend toward an increase in the number of cases of acute hepatitis B and in the proportion of amplicons bearing the HBV PV C gene sequence is clearly evident: by 1995 and 1996, an overwhelming majority of serum samples were carrying the HBV PV C gene sequence. Changes in the proportion of serum samples carrying HBV PV for the 3 laboratories are summarized in figure 3 . The increase in the proportion of samples carrying HBV PV was significant for samples from the Hull laboratory ( , by the x 2 test P ! .01 for linear trend) but not for samples from the CPHL and Birmingham laboratory. Although the differences among the 3 laboratories in the proportion of samples carrying HBV PV were not significant for 1990 and 1993, the differences were significant for 1994 and 1995 ( and , respectively, P p .017 P ! .0001 by the x 2 test). Of the 58 case patients from Hull who were infected with HBV PV , 26 (45%) were IDUs, and 12 (21%) had a history of imprisonment; no risk information was available for the 20 other case patients (34%). Of the 26 case patients from Birmingham who were infected with HBV PV , risks associated with acute hepatitis B were as follows: male homosexual intercourse, 7 case patients (27%); overseas travel, 3 case patients (12%); injection drug use, 2 case patients (8%); heterosexual intercourse, 2 case patients (8%); medical treatment/injections, 2 case patients (8%); and body piercing, 1 case patient (4%). For 5 case patients (19%), no risk was identified, and no information was available for 4 case patients (15%). 
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HBV has a low rate of endemicity in the United Kingdom [1] . Previous molecular studies of outbreaks [5] [6] [7] [8] [9] [10] [11] [12] have supported the assumption that sporadic cases and outbreaks of acute hepatitis B are caused by HBV variants unlinked to one another. On the contrary, the studies described here show that a significant proportion of outbreaks of HBV infection and of transmission incidents are associated with a particular variant of HBV, HBV PV . To the best of our knowledge, defined HBV variants circulating in a population have not been described in the scientific literature. The closest example is a study of 30 epidemiologically unlinked patients with acute HBV infection in Samara, a Russian city [16] . In that study, a large majority of patients was found to carry HBV with identical subgenomic sequences, but the analysis was not extended to the determination of how the predominantly circulating variant was transmitted over time.
We first identified HBV PV in the clusters of cases of acute hepatitis B that occurred from 1992 through 1994 among inmates of prisons in northern England, and we found that 180% of the cases were associated with this particular HBV variant. We attribute these outbreaks to the sharing of needles and other equipment for the injection of narcotics. Prisons provide a unique environment for the transmission of bloodborne infections, owing to high-risk behaviors such as injection drug use and, to a lesser extent, men having sex with men [17] [18] [19] [20] . Also, vaccination programs for the prevention of HBV infection have not been well implemented in prisons [19, [21] [22] [23] [24] . None of the inmates included in this study had been vaccinated prior to infection.
Application of a high-throughput assay involving DGGE of serum samples from case patients from 3 regions of England who had received a diagnosis of acute hepatitis B between 1990 and 1996 revealed that HBV PV was widespread in the country prior to, contemporaneous with, and following the outbreaks in the prisons. The high prevalence of HBV PV was indicated by the findings that 16%-37% of the set of study serum samples from the CPHL (mostly representing cases of acute hepatitis B in southeast England) and 25%-70% of the serum samples from the Birmingham laboratory (reflecting cases of acute hepatitis B in the West Midlands) contained HBV PV ( figure 3 ). Although no trend toward an increase in the proportion carrying HBV PV was observed for the samples from the CPHL and the Birmingham laboratory, a notable trend of an increase in the proportion of samples referred by the Hull laboratory was observed. This increase corresponded with the appearance of an outbreak of acute hepatitis B in the community that began in 1994 (figures 2 and 3), implicating HBV PV as the cause of the outbreak. Risk analysis showed that the increase in HBV PVassociated cases in North Humberside was associated with imprisonment and injection drug use. People released from prison tend to change sexual partners frequently and to continue to engage in injection drug use [3, 18, 19, 23] . Whether the community outbreak of acute hepatitis B was linked to the outbreaks in the Hull prisons in 1994 cannot formally be ascertained, although the chronology of events and the high proportion of former prison inmates among the case patients in the community are consistent with such a linkage.
That HBV PV may be found in subpopulations other than those consisting of IDUs and people with a history of imprisonment is suggested from the risk analysis for the HBV PVinfected case patients in the West Midlands. The analysis showed that sexual contact (both homosexual and heterosexual), rather than injection drug use or imprisonment, was the dominant risk factor associated with acute HBV PV infection. Analysis of the outbreaks of HBV infection and of other transmission incidents investigated by the CPHL from 1995 through 2002 also showed that HBV PV could be carried by a variety of people other than those who admitted to being IDUs; these people included a surgeon, blood donors, and customers of a tattoo parlor (table 1) . Nonetheless, the prevalence of HBV PV among IDUs remained high, as exemplified by the clusters of cases in Norwich (cluster 8) and in Leicester (cluster 9).
The larger DNA fragment that we studied encompassed codons 40-174 of the HBV S gene, which brackets the major hydrophilic region of HBsAg. Mutations associated with vaccine escape and weak HBsAg signals in serological assays are located in this domain [25] . We sought such mutations and found HBV PV to be a wild-type variant. We did not look for mutations in the pre-C gene domain, some of which are known to abrogate the production of hepatitis B e antigen (HBeAg) [25] , because serological testing of the original prison inmates infected with HBV PV had shown that the case patients carried HBeAg.
Despite the involvement of HBV PV in many chains of infection during ∼10 years, no sequence changes were observed in the S and C genes. We found this to be surprising, particularly because these genes tend to carry more hypervariable loci than other HBV genomic domains [26] . Phylogenetic analysis that included other genotype A sequences from investigations of transmission incidents revealed several very closely related S gene sequences (figure 4). Analysis of more of the genome would indicate whether HBV PV and closely related sequences should be considered a distinct variant family or quasi species and to what extent they have penetrated the population of circulating HBV in the United Kingdom [27] . Whether such stability is specific to HBV PV or whether it could be conferred on any HBV variant that found a niche (such as among IDUs) favoring rapid and continuing transmission from hosts with acute infection is unknown.
One important consequence of a particular HBV sequence being maintained over a long period despite transmission through many cycles of infection is that epidemiological inferences about causation and transmission could be con-founded. Nucleotide-sequencing assays increasingly are being used to establish that a particular HBV variant is carried by the source of a cluster of cases of HBV infection and to track chains of HBV transmission [5, 7-10, 12, 28-32] . When the same or very similar subgenomic sequences are identified, the conclusion reached is that recent transmission has occurred between infected individuals. In view of our findings, the use of PCR sequencing alone cannot be the basis for implicating an HBV variant in transmission events without a survey of HBV genomes concurrently in circulation. Reliance must continue to be placed on other, carefully collected epidemiological data. When the epidemiological and molecular data are correlated, insights into the source and spread of HBV infection may be revealed.
